1. Academic Validation
  2. 68Ga-DOTA-GGNle-CycMSHhex targets the melanocortin-1 receptor for melanoma imaging

68Ga-DOTA-GGNle-CycMSHhex targets the melanocortin-1 receptor for melanoma imaging

  • Sci Transl Med. 2018 Nov 7;10(466):eaau4445. doi: 10.1126/scitranslmed.aau4445.
Jianquan Yang 1 Jingli Xu 1 Rene Gonzalez 2 Thomas Lindner 3 Clemens Kratochwil 4 Yubin Miao 5
Affiliations

Affiliations

  • 1 Department of Radiology, University of Colorado Denver, Aurora, CO 80045, USA.
  • 2 Department of Medical Oncology, University of Colorado Denver, Aurora, CO 80045, USA.
  • 3 Department of Nuclear Medicine, University Hospital Heidelberg, 69120 Heidelberg, Germany.
  • 4 Department of Nuclear Medicine, University Hospital Heidelberg, 69120 Heidelberg, Germany. yubin.miao@ucdenver.edu clemens.kratochwil@med.uni-heidelberg.de.
  • 5 Department of Radiology, University of Colorado Denver, Aurora, CO 80045, USA. yubin.miao@ucdenver.edu clemens.kratochwil@med.uni-heidelberg.de.
Abstract

Melanocortin-1 receptor (MC1R) is a molecular target for melanoma imaging and therapy because of its overexpression on rodent and human melanoma cells. Here, we evaluated the MC1R targeting and specificity of 68Ga-DOTA-GGNle-CycMSHhex and Cy5.5-GGNle-CycMSHhex using murine and human melanoma cells, and murine and xenografted tumors. 68Ga-DOTA-GGNle-CycMSHhex was used first in human as an imaging probe to evaluate the possibility of radionuclide therapy in patients with advanced-stage melanoma. 68Ga-DOTA-GGNle-CycMSHhex and Cy5.5-GGNle-CycMSHhex displayed MC1R-specific targeting properties in murine and human melanoma cells, as well as in murine melanoma and human melanoma-xenografted tumors. Both B16/F10 and M21 melanoma lesions could be easily imaged by positron emission tomography using 68Ga-DOTA-GGNle-CycMSHhex The first-in-human images of melanoma brain metastases in patients demonstrated the clinical relevance of MC1R as a molecular target for melanoma imaging, highlighting the potential of 68Ga-DOTA-GGNle-CycMSHhex as an MC1R-targeting melanoma imaging probe and underscoring the need to develop MC1R-targeting therapeutic agents for treating patients with metastatic melanoma.

Figures
Products